



Detection of Deregulated miRNAs in Childhood Epileptic Encephalopathies

Aycan Ünalp¹ · Ender Coskunpinar² · Kubra Gunduz² · Serdar Pekuz³ · Bahar Toklu Baysal³ · Selvinaz Edizer³ · Ceyda Hayretdag⁴ · Elif Gudeloglu³

Received: 25 November 2021 / Accepted: 15 March 2022 / Published online: 24 April 2022
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022

Abstract

The term “epileptic encephalopathy” is used to describe a possible relationship between epilepsy and developmental delay. The pathogenesis of developmental encephalopathies, independent of epilepsy, can be defined by genetic control mechanisms. The aim of this study was to investigate the use of miRNAs as serum biomarkers for the determination and discrimination of epileptic encephalopathies. Whole blood samples obtained from 54 individuals in 2 groups designated as epileptic encephalopathy patients’ group ($n=24$) and healthy controls ($n=30$) were included in this study. The expression levels of 10 miRNAs were determined using qRT-PCR. After the determination of expression levels, the correlation of upregulated miRNA levels and Ki67 index was calculated using Pearson correlation test. The comparison of epileptic encephalopathy patients’ group with healthy controls revealed the upregulation of one miRNAs (hsa-miR-324-5p) and downregulation of three miRNAs (hsa-miR-146a-5p, hsa-miR-138-5p, hsa-miR-187-3p). It has been determined that miRNAs with altered expression are an important factor in the formation of epileptic seizures and seizure-induced neuronal death. The fact that processes that play a key role in epileptogenesis are under the control of miRNAs causes miRNAs to become meta-controllers of gene expression in the brain. We thought that further studies are needed to prove that especially hsa-miR-146a-5p, hsa-miR-138-5p, and hsa-miR-187-3p can be used as epileptic encephalopathy biomarkers. The detection of disease-specific miRNAs could contribute to the development of precision treatments.

Keywords Epileptic encephalopathy · Childhood · Biomarker · microRNA · Precision medicine

Introduction

Epilepsy is a common neurological disorder in childhood defined as seizures that occur because of neuronal discharge in a specific region of the brain (Li et al. 2020). The

incidence of the disease in children varies between 33 and 82 per 100,000 per year (Wu et al. 2019). Drug-resistant epilepsy (DRE) is defined as the persistence of seizures despite adequate anti-epileptic treatment with two or more anti-epileptic drugs at efficacious daily doses, alone or in

✉ Aycan Ünalp
aycanunalp67@gmail.com

Ender Coskunpinar
ecoskunpinar@gmail.com

Kubra Gunduz
gunduzkubra@gmail.com

Serdar Pekuz
pekuzserdar@hotmail.com

Bahar Toklu Baysal
bahartoklu@hotmail.com

Selvinaz Edizer
selvisim@yahoo.com

Ceyda Hayretdag
hayretdag@yahoo.com

Elif Gudeloglu
drelif55@hotmail.com

¹ Department of Pediatric Neurology, Izmir Faculty of Medicine, University of Health Sciences, Izmir, Turkey

² Department of Medical Biology, School of Medicine, University of Health Sciences, Istanbul, Turkey

³ Department of Pediatric Neurology, University of Health Sciences, Dr. Behcet Uz Children’s Training and Research Hospital, Izmir, Turkey

⁴ Department of Neurology, School of Medicine, Beykent University, Istanbul, Turkey

combination, and affects approximately 30% of children with epilepsy. Nowadays, it has been defined as not pharmacoresponsive epilepsies. The most severe forms of drug-resistant epilepsy usually begin in childhood (Patel and Mercimek-Mahmutoglu 2016). In patients with epilepsy related to a genetic etiology, drug resistance is particularly frequent, especially in those with severe developmental and epileptic encephalopathies (Guery and Rheims 2021).

Epileptic encephalopathy is defined by the presence of frequent epileptiform activity that causes slowing or regression of developmental skills. It is known that many of the epileptic encephalopathies have a molecular genetic basis. The fact that genetic etiology alone can cause developmental impairment means that individualized treatments should be developed to prevent the devastating consequences of this disease group (Scheffer and Liao 2020). According to the 2010 International League Against Epilepsy (ILAE) classification and terminology commission, epileptic encephalopathy is defined as conditions in which epileptic activity causes serious cognitive and behavioral disorders and may worsen over time, beyond what is expected from the existing pathology (Berg et al. 2010). Childhood EE are classified as infantile spasms, Dravet syndrome, Lennox–Gastaut syndrome, epileptic encephalopathy with electrical status during slow sleep (ESES), and Landau–Kleffner syndrome, etc. The common feature of these syndromes is that they are generally resistant to antiseizure drugs (ASD) (Engel 2001). The response to (ASD) is generally poor despite high-dose polytherapy. The most common application used in the treatment of EE patients is adrenocorticotrophic hormone (ACTH). However, ACTH causes side effects with high morbidity and mortality, such as hyperglycemia, hypertension, immunodeficiency, and iatrogenic Cushing's syndrome (Khan and Al Baradie 2012).

Understanding what controls gene expression may open new avenues for the treatment or prevention of epileptic encephalopathy (Fisher et al. 2014). Therefore, the development of new treatment targets and strategies in epileptic encephalopathies will reduce the risk of mortality and morbidity due to seizures and drugs used by individuals with this disease. For this purpose, identifying the relevant pathways and molecular mechanisms that coordinate gene expression is crucial for a better understanding of the pathogenic process and the development of new therapeutic approaches.

microRNA (miRNA) is a class of small (19–25 nucleotide), single-stranded, endogenous, non-protein-coding short RNA molecules that regulate gene expression either by promoting mRNA degradation or attenuating protein translation at the post-transcriptional level (Reschke and Henshall 2015). miRNAs are initially transcribed by polymerase II (Pol II) as primary transcripts (pri-miRNA), processed into pre-miRNA, and finally converted to mature miRNA by RNases called Drosha and Dicer, respectively.

The functional strand of mature miRNA is loaded into the RNA-induced silencing complex (RISC) containing the Argonaute 2 (Ago-2) protein. The RISC-loaded miRNA is then directed to silencing the target mRNA via mRNA degradation or translation inhibition. A given miRNA can have several binding sites to the same mRNA, and a single mRNA can be targeted by more than one miRNA, thus producing stronger effects. In line with this view, a single miRNA can regulate the expression of hundreds of genes, thus presenting important effects on cellular functions (Esquela-Kerscher and Slack 2006). They mainly function to lower protein levels in cells through sequence-specific binding to target mRNAs, leading to transcript degradation or translational repression.

More than 50% of the miRNAs identified are expressed in the brain. The brain has a variety of miRNAs that are crucial for the establishment and maintenance of normal development and cell phenotype. Acute and chronic nervous system diseases, including epilepsy, are associated with dysregulation of key components of the miRNA biogenesis pathway and altered expression of miRNA. miRNAs are implicated in many brain functions important for epileptogenesis, including cell death, neurogenesis, and synaptic plasticity (Karnati et al. 2015). Studies on associating the development of epilepsy with miRNA have gained momentum in the last 10 years. Large-scale miRNA profiling studies that characterize changes in the expression of different miRNAs are carried out, especially in animal models and subsequent experimental studies with human blood and tissue samples (Mooney et al. 2016). Recently, functional studies in rodents have shown that miRNAs can have potent effects on brain excitability, seizures, and epilepsy. It has been reported that targeting miRNAs, which play a key role in epilepsy, suppresses or exacerbates seizures and alters brain excitability, which has a potential for miRNA-based therapeutics in epilepsy (Reschke and Henshall 2015).

In this study, it was aimed to determine the expression levels of 10 different miRNAs (hsa-miR-23a-3p, hsa-miR-34a-5p, hsa-miR-132-3p, hsa-miR-146a-5p, hsa-miR-134-5p, hsa-miR-30a-5p, hsa-miR-138-5p, hsa-miR-324-5p, hsa-miR-330-3p, hsa-miR-187-3p) thought to be deregulated in childhood epileptic encephalopathy patients and to reveal the disease formation process.

Material and Methods

Study Design

A total of 54 samples from 30 healthy controls and 24 epileptic encephalopathy patients were included in the study. Blood samples were taken from volunteers who were pre-diagnosed in Health Sciences University, Dr. Behçet Uz

Children's Training and Research Hospital, Department of Pediatric, Division of Pediatric Neurology outpatient clinics, aged between 1 month and 18 years, who underwent electroencephalogram (EEG), brain magnetic resonance imaging (MRI), and metabolic tests and were diagnosed with EE. Control group samples were taken from healthy individuals matched for age and sex. The study was approved by the Clinical Research Ethics Committee of Izmir Dr. Behçet Uz Children's Training and Research Hospital (Project No: 2019/084, Ethical Approval No: 2019/07–07). After all, individuals included in the study or their parents read and signed the informed consent form, and 2 ml peripheral blood samples were taken into EDTA tubes for miRNA isolation and centrifuged at 3000 rpm for 10 min for serum separation from blood. Serum samples were stored at -80°C until the study was carried out and transferred to the Health Sciences University Medical Biology Department by the cold chain for miRNA isolation.

miRNA Extraction and cDNA Synthesis

miRNA isolation was performed from serum samples using the miRNeasy Serum/Plasma Advanced Kit (Qiagen, Hilden, Germany, Cat. No: 217204) according to the manufacturer's instructions. Next, cDNA synthesis from miRNAs was performed using the miRCURY LNA RT Kit (Qiagen, Hilden, Germany, Cat. No: 339340) according to the manufacturer's instructions. To determine the purity and concentration of cDNA samples, cDNA control PCR and melting curve analysis were performed.

qRT-PCR

Pre-designed primers were used for real-time PCR to determine miRNA expression levels of all samples (Table 1). In total, a gene panel was constructed with specific primers and one housekeeping primer for 10 different miRNAs (miRCURY LNA miRNA Custom PCR Panels, Qiagen, Hilden,

Germany). Real-time PCR reactions were performed in triplicate on a Light-Cycler 480 II (Roche) instrument following the manufacturer's protocol using the miRCURY LNA SYBR Green PCR Kit (Qiagen, Hilden, Germany, Cat. No: 339346). Thermal cycling conditions were performed at 95°C for 10 min, then at 95°C for 15 s, at 60°C for 1 min, and at 72°C for 10 s for 45 cycles. PCR specificity was confirmed by melting curve analysis.

Statistical Analysis

SPSS 25.0 was used for statistical analysis. The significance of miRNA expression levels was calculated by performing a *t* test on $2-\Delta\text{Ct}$ values for each different miRNA. For the analysis of continuous variables, the Shapiro–Wilk test and Levene's test was facilitated to investigate the distribution and variance homogeneity. Parametric continuous values were compared with *t* test and ANOVA, while non-parametric variables were compared with Mann–Whitney *U* and Kruskal–Wallis tests. Categorical variables were analyzed by chi-square tests. Significant correlations between the expression data and clinical parameters were assessed by calculating the Pearson correlation coefficient. The obtained data were analyzed with an online software program (miRCURY LNA miRNA PCR Panels and Assay) developed by Qiagen GeneGlobe Data Analysis Center. The expression levels of each miRNA were evaluated using the Ct (Threshold Cycle) value. These results were normalized for each sample using the SNORA66 housekeeping gene (ΔCt). The relative amount of each miRNA to SNORA66 was described by the equation $\Delta\text{Ct} = (\text{Ct miRNA} - \text{Ct SNORA66})$. Fold changes between control and patient were calculated as $2^{-\Delta\Delta\text{Ct}}$. The N-fold differential expression of the miRNA gene of the patient sample compared with the control was expressed as $2^{-\Delta\Delta\text{Ct}}$. The mean values of fold difference for epileptic encephalopathy patients were compared with the mean values obtained from control samples. In this study, miRNAs with fold change ≥ 2 were considered deregulated.

Results

Demographic and Clinical Characteristics of the Study Population

The demographic and clinical characteristics of both case and control groups were summarized in Table 2. The mean ages for EE patients and healthy control groups were 0.1 ± 8.77 and 0.1 ± 11.02 , respectively. When the EEG findings of the patients were examined, 7 patients showed Lennox–Gastaut syndrome, 2 patients showed generalized epileptic activity, 2 patients showed Focal ESES, 6 patients showed focal epileptic activity, and 5 patients showed modified hypersarrhythmia. When the patients were evaluated in

Table 1 miRNA primer list

miRNA	Target sequence (5' -> 3')
hsa-miR-23a-3p	AUCACAUUGCCAGGGAAUUUC
hsa-miR-34a-5p	UGGCAGUGUCUUAGCUGGUUGU
hsa-miR-132-3p	UAAACAGUCUACAGCCAUGGUCG
hsa-miR-146a-5p	UGAGAACUGAAUCCAUGGGUU
hsa-miR-134-5p	UGUGACUGGUUGACCAGAGGGG
hsa-miR-30a-5p	UGUAAACAUCCUCGACUGGAAG
hsa-miR-138-5p	AGCUGGUGUUGUGAAUCAGGCCG
hsa-miR-324-5p	CGCAUCCCUAGGGCAUUGGUGU
hsa-miR-330-3p	GCAAAGCACACGGCCUGCAGAGA
hsa-miR-187-3p	UCGUGUCUUGUGUUGCAGCCGG

Table 2 The demographic and clinical characteristics of both case and control groups were demonstrated

Patient No	Age (month)/sex	Age at onset of seizures	Types of seizures	IED in EEG	MRI of brain	Applied treatment modalities	Muscle tone	Other manifestations
1	90/M	4 years	T, M	Generalized	Normal	ASDs, KD	<i>N</i>	Ataxia, hypogammaglobulinemia
2	150/M	2.5 years	A, M, Abs	Focal + generalized	Periventricular leukomalacia	ASDs, HT, VNS	<i>N</i>	
3	218/F	10 years	M	Focal + generalized	Normal	ASDs, HT, VNS, KD	<i>N</i>	Gallstone
4	139/M	2 days	ES, T, M	Focal	Parieto-occipital leukomalacia	ASDs, HT	<i>N</i>	Microcephaly, nystagmus
5	84/F	12 months	T, C, GTC	Focal + generalized	Parietal subcortical leukomalacia	ASDs, KD	<i>N</i>	
6	216/F	9 months	T, C, A, Abs	Focal + Generalized	Agyria, pachygyria, lissencephaly	ASDs, HT, VNS		
7	183/F	2 years	A, M, Abs	Focal + generalized	Arachnoid cyst	ASDs, HT	<i>N</i>	
8	144/M	8 months	T, C, gelastic	Multifocal + generalized	Parieto-occipital leukomalacia	ASDs	Hypotonic	
9	168/M	7 months	Focal to bilateral TC	Focal + generalized	Lissencephaly, pachygyria, brain stem, & cerebellar atrophy	ASDs	<i>N</i>	
10	144/M	12 months	BA, automatism	Multifocal + generalized	Diffuse cerebral atrophy, mild ventriculomegaly	ASDs, KD	Hypotonic	Tracheostomy, gastrostomy
11	84/F	12 months	M, GTC, BA, automatism	Focal + generalized	Diffuse cerebral atrophy	ASDs	Hypotonic	Gastrostomy
12	132/F	6 months	T, M	Focal + generalized	Diffuse cerebral & cerebellar atrophy, ischemic changes	ASDs, KD	Hypotonic	Gastrostomy
13	39/F	7 months	ES, T, M, BA	Multifocal + generalized	Multicystic encephalomalacia, hypoplasia of CC	ASDs, HT, KD	Hypotonic	Microcephaly
14	122/F	3 months	ES, T, M, BA	Focal	Diffuse cerebral atrophy, mild ventriculomegaly	ASDs, KD	Hypotonic	Microcephaly
15	39/M	8 months	ES, T, BA	Focal + generalized	Periventricular leukomalacia	ASDs	Hypotonic	Microcephaly
16	306/M	2.5 years	M, BA	Focal + generalized	Normal	ASDs	<i>N</i>	Ataxia
17	84/M	2 years	ES, focal to bil. TC, M	Focal + generalized	Diffuse cerebral atrophy, hypomyelination	ASDs	Hypotonic	Microcephaly, gastrostomy
18	84/F	3 months	T, M	Focal + generalized	Hypomyelination	ASDs	Hypotonic	
19	66/F	2 years	M, Abs	Generalized	Normal	ASDs	<i>N</i>	
20	147/M	6 months	T, M	Multifocal	Normal	ASDs	Hypotonic	Microcephaly, nystagmus
21	153/F	2 months	ES, C	Focal	Normal	ASDs, HT, KD	Hypotonic	
22	151/M	12 months	C	Focal + generalized	Normal	ASDs	Hypotonic	
23	62/F	10 months	ES, T, M, C	Focal + generalized	Normal	ASDs, HT	Hypotonic	Microcephaly
24	36/F	8 months	Focal to bil. TC, T, autonomic	Focal + generalized	Hypomyelination	ASDs	<i>N</i>	

A atonic, *Abs* absence, *BA* behavior arrest, *C* clonic, *ES* epileptic spasm, *GTC* generalized tonic–clonic, *M* myoclonic, *T* tonic, *TC* tonic–clonic, *ASDs* anti-seizure drugs, *HT* hormonal therapy (glucocorticoids or corticotropin), *KD* ketogenic diet, *VNS* vagal nerve stimulation

terms of developmental and behavioral disorders, mental retardation was found in 18 patients, growth retardation in 4 patients (cognitive retardation in 1 patient, global growth retardation in 1 patient, growth, and development retardation in 2 patients), autism in 1 patient, and normal psychomotor development in 1 patient.

miRNA Deregulation in Epileptic Encephalopathy Patients

To determine the expression levels of 10 different miRNAs (Table 3) that are thought to be deregulated in epileptic encephalopathy patients compared to healthy controls, serum miRNA expression levels were determined by the qRT-PCR method in 30 healthy controls and 24 epileptic encephalopathy patients.

Differential Expression in Epileptic Encephalopathy Patient Group in Comparison to Healthy Controls

In comparison to control group, 8 miRNAs have shown significant deregulation in epileptic encephalopathy patient group (Fig. 1). Out of these 8 miRNAs, 1 was upregulated, while 7 miRNAs were downregulated (Fig. 2.). No significant difference was found in 2 miRNAs. The most substantially upregulated miRNA was hsa-miR-324-5p (FC324-5p=2.07, p324-5p=0.0032158), while as downregulated hsa-miR-187-3p, hsa-miR-146a-5p, hsa-miR-138-5p, hsa-miR-23a-3p, hsa-miR-30a-5p, hsa-miR-330-3p, and hsa-miR-34a-5p have shown the most fold change (FC187-3p= -37.22, p187-3p = 0.000079; FC146a-5p = -31.44, p146a-5p=0.000102; FC138-5p= -8.22, p138-5p=0.003782, FC23a-3p= -5.29, p23a-3p=0.943002, FC30a-5p= -4.32, p30a-5p=0.074398, FC330-3p= -2.09, p330-3p=0.051443, FC34a-5p=2.31, p34a-5p=0.265964).

Table 3 Fold regulations and *p* values

miRNA	Fold regulation	<i>p</i> values
hsa-miR-23a-3p	-5.29	0.94
hsa-miR-34a-5p	-2.31	0.26
hsa-miR-132-3p	1.12	0.33
hsa-miR-146a-5p	-31.44	*0.0001
hsa-miR-134-5p	-1.16	0.06
hsa-miR-30a-5p	-4.32	0.07
hsa-miR-138-5p	-8.22	*0.003
hsa-miR-324-5p	2.07	*0.03
hsa-miR-330-3p	-2.09	0.051
hsa-miR-187-3p	-37.22	*0.00007

p value < 0.05 was considered statistically significant

Discussion

Children with EEs are in the risk group in terms of developmental problems, mental status disorders, and comorbidities such as physical problems. The cognitive outcome is not only related to the cause but also appropriate treatments, such as hormonal therapy or early surgical treatment in cases with focal cortical dysplasia (Sisodiya 2020). In our study, only one patient had normal neuromotor development, and most of the remaining patients had mental motor retardation, as well as any autism, growth and developmental retardation, global developmental retardation, and cognitive retardation.

In recent epilepsy genetics studies, miRNAs are important regulators of gene expression (Mooney et al. 2016). The failure of preclinical trials targeting genes encoding proteins that are effective in the development of epilepsy to prevent epileptogenesis has contributed to the prominence of miRNAs (Pitkanen and Lukasiuk 2011). The fact that processes that play a key role in epileptogenesis, such as neuronal death, gliosis, inflammation, and reorganization of neuronal networks, is under the control of miRNAs, causing miRNAs to become meta-controllers of gene expression in the brain (Dogini et al. 2013). Therefore, researchers are trying to determine their potential as biomarkers by manipulating miRNAs in vivo to understand the function of miRNAs that play a role in epilepsy. It has been determined that miRNAs with altered expression are an important factor in the formation of epileptic seizures and seizure-induced neuronal death (Jimenez-Mateos et al. 2012). Approximately 100 miRNAs with varying expression levels were detected in miRNA profile screening studies performed with tissues isolated from the hippocampus resected from patients with temporal lobe epilepsy (Kan et al. 2012; McKiernan et al. 2012).




Fig. 1 miRNA fold regulation graphic

According to the results of these studies, miR-146a and miR-132 are upregulated, while miR-30a/b, miR-138, miR-324, miR-330 (Bot et al. 2013a, b), and miR-187 (Gorter et al. 2014) are downregulated. The first microRNA shown to regulate susceptibility to seizures was miR-134, which has an anticonvulsant effect when inhibited with antisense oligonucleotides prior to a seizure-inducing treatment (Jimenez-Mateos et al. 2012). They detected that the expression level of miR-134 was increased in epilepsy and silencing of miR-134 caused a significant reduction in induced and spontaneous seizures. *Limk1*, the target gene of miR-134, is an important protein that plays a role in the control of the dendritic structure, which is a critical contact point for excitatory transmission in the central nervous system. In recent years, microRNAs such as miR-132, miR-146a, miR-34a, miR-128, miR-324-5p, and miR-124 have also been shown as positive or negative regulators of neuronal hyperexcitability (Tiwari et al. 2018). miR-146a has been shown to be strongly expressed in the central nervous system (CNS) and plays an important role in the regulation of the innate immune response induced in these tissues in association with neurodegenerative disorders. Aronica et al. (2010) is the first to report altered expression pattern of miR-146a in epileptic rats and temporal lobe epilepsy patients. Recently, miRNA expression profile analyses of samples under epilepsy conditions showed that miR-146a is significantly upregulated in the hippocampus of both the TLE rat model and epilepsy patients, and miR-146a also interacts with IL-1 β at different stages of epilepsy. It has been proven that miR-146a has a key role in the cell cycle control, acquisition of neuronal identities, differentiation of neural cells, and regulation of the immune responses in the CNS. Its abnormal expression is among the most common events in the pathogenesis of

neurological disorders (Nguyen et al. 2018; Mei et al. 2011). As can be seen, conflicting results regarding miR-146a expression have been reported in various publications. In our study, miR-146a showed downregulation. We explain this situation with the effect of miR-146a on the regulation mechanism of immune response. NF- κ B signaling pathway activation induces miRNA gene expression. Negative regulation of this pathway activity is performed by miR-146a (Taganov et al. 2006). This miRNA acts as a post-transcriptional negative regulator in the immune cells by affecting TLRs, especially TLR4, and targeting IL-1 receptor-associated kinase (IRAK) 1 and TNF receptor-associated factor (TRAF) 6 adapter molecules (Doxaki et al. 2015). The lack of miR-146a expression is associated with impaired Treg function, loss of peripheral T lymphocyte tolerance, and autoimmunity occurrence (Boldin et al. 2011; Lu et al. 2010). We are investigating the miRNA expression levels of these target genes (IL-1, NF- κ B, IRAK1, and TRAF6) related to the immune response, which we think may be relevant, as part of our ongoing project. An article made with cell lines published by Qin et al. in July 2021 reported that the miR-138-5p gene is a miRNA targeting caspase-3 to control apoptosis (Qin et al. 2021). In this study, it was reported that miR-138-5p is directly associated with the proliferation and survival of human multiple myeloma cells. We think that miR-138-5p, which was found to be downregulated in our study, triggers apoptosis, negatively affects cell survival, and causes damage to many brain functions that are important for epileptogenesis. Several studies have shown that miR-187 is downregulated in patients with TLE. Kretschmann et al. (2015) found a significant downregulation of miR-187 expression in the 28-day pilocarpine-induced SE in mice. Bot et al. (2013a, b) reported a downregulation of this miRNA 30 days after SE induced by amygdala electrical stimulation. Gorter et al. (2014) detected a significant downregulation of miR-187 at 3–4 months following status epilepticus induced by electrical stimulation of the angular beam in rats. Several studies have suggested a link between miR-187 and chronic human inflammatory diseases (Holliday et al. 2011; Suojalehto et al. 2014). In animal studies and clinical observations, inflammation-associated miRNAs have been found to be deregulated during the chronic phase of TLE (Omran et al. 2012; Ashhab et al. 2013). Evidence obtained from both in vitro and in vivo experiments indicated that miR-187-3p is involved in CFC memory (Zhao et al. 2020). In an article published in 2017 by Suya Zhang et al. the potential binding sites of miRNAs and their target genes were analyzed. rno-miR-187-3p was downregulated in stimulated groups compared to controls. Seven distinct genes were identified in the genome as predicted target genes of rno-miR-187-3p. The results obtained in our study overlap with these results (Zhang et al. 2017). In an article by Dakterzada et al. in Alzheimer's patients and published in 2020, miR-324-5p expression was found to be upregulated (Dakterzada et al. 2020). Also, according to Gross et al. (2016) study, inhibiting miR-324-5p




Fig. 2 Fold regulation graphic

is neuroprotective and increases the delay to seizure onset in mouse models of status epilepticus. The upregulation of the miR-324-5p gene, which is known to cause cortical dysplasia, which is reported to be upregulated in many cancer types such as chronic pancreatitis, colon cancer, and breast cancer, was also found to be upregulated in our study, in line with the literature (Kalser and Cross 2018; Wang et al. 2017).

Developmental delay in children with epilepsy may be the result of intense epileptiform activity (seizures and EEG abnormalities) or a combination of related factors. However, these seizures do have an impact on the quality of life, as well as the patient's safety, and as such need intervention. Therefore, the current "International League Against Epilepsy" classification has defined three electroclinical conditions: "developmental encephalopathy," "epileptic encephalopathy," and "developmental and epileptic encephalopathy" (DEE). Many biological pathways may play a role in the pathogenesis of DEEs. DNA repair, transcriptional regulation, axon myelination, metabolite and ion transport, and paroxysmal function may all be involved in DEE (Hamdan et al. 2017; Raga et al. 2021).

Although miRNA studies have been performed in adulthood, especially in mesial temporal lobe epilepsy, this rate is very limited in childhood epilepsy. In recent years, the fields of RNA-based therapy have advanced considerably, and miRNAs offer powerful new features in this field. A study on miRNA expression only in cases with EE was not found in the literature review. Many biological pathways may play a role in the pathogenesis of DEEs. Among these, channelopathies and synaptic dysfunctions are the most common (He et al. 2019). Causes of DEEs include disruption of other cellular functions, DNA repair, transcriptional regulation, axon myelination, metabolite, and ion transport, and peroxisomal function (McTague et al. 2016). Understanding the genetic causes of EE is essential for targeted therapies. By uncovering the pathogenetic mechanism and neurobiological processes, it may be possible to improve not only seizure control but also developmental outcome and disease-related comorbidities. However, there is a need to develop new and safe therapeutic drugs, particularly through preclinical research, to evaluate how these therapeutic interventions can be administered safely without causing unwanted side effects such as the currently widely prescribed ASDs (Tecuapetla et al. 2020).

Conclusion

Determining the molecular mechanisms of these miRNAs, which play a role in the development of EE, is very important for the development of precision treatments. In this study, we detected deregulated expression levels of four of the miRNAs. We hope that our study will shed light on

further studies and that these disorders can be treated better with supportive research.

Author Contribution Aycan Unalp and Ender Coskunpinar designed the study; Aycan Unalp, Serdar Pekuz, Bahar Toklu Baysal, Selvinaz Edizer, Ceyda Hayretdag, and Elif Gudeloglu obtained the samples; Aycan Unalp, Ender Coskunpinar, Kubra Gunduz, Serdar Pekuz, Bahar Toklu Baysal, Selvinaz Edizer, Ceyda Hayretdag, and Elif Gudeloglu drafted and revised the manuscript; Ender Coskunpinar and Kubra Gunduz acquired, analyzed, and interpreted the data. All authors read and approved the manuscript.

Funding The present work was supported by the research fund of the University of Health Sciences. Project No. 2019/84.

Availability of Data and Materials The data used to support the findings of this study are available from the corresponding author upon request.

Declarations

Ethics Approval and Consent to Participate All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Clinical Research Ethics Committee of Izmir Dr. Behçet Uz Pediatrics and Surgery Training and Research Hospital (Project No: 2019/084, Ethical Approval No: 2019/07–07). All procedures were followed in accordance with Helsinki Declaration of 1975, as revised in 2000. Informed consent was taken from all patients included to the study.

Consent for Publication Not applicable.

Competing Interests The authors declare no competing interests.

References

- Aronica E, Fluiter K, Iyer A, Zurolo E, Vreijling J, Van Vliet EA, Gorter JA (2010) Expression pattern of miR-146a, an inflammation-associated microRNA, in experimental and human temporal lobe epilepsy. *Eur J Neurosci* 31(6):1100–1107. <https://doi.org/10.1111/j.1460-9568.2010.07122>
- Ashhab MU, Omran A, Kong H, Gan N, He F, Peng J, Yin F (2013) Expressions of tumor necrosis factor alpha and microRNA-155 in immature rat model of status epilepticus and children with mesial temporal lobe epilepsy. *J Mol Neurosci* 51(3):950–958. <https://doi.org/10.1007/s12031-013-0013-9>
- Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde Boas W, Scheffer IE (2010) Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology 2005–9. *Epilepsia* 51:676–85. <https://doi.org/10.1111/j.1528-1167.2010.02522.x>
- Boldin MP, Taganov KD, Rao DS, Yang L, Zhao JL, Kalwani M, Baltimore D (2011) miR-146a is a significant brake on autoimmunity, myelopoiesis, and cancer in mice. *J Exp Med* 208(6):1189–1201. <https://doi.org/10.1084/jem.20101823>
- Bot AM, Debski KJ, Lukasiuk K (2013a) Alterations in miRNA levels in the dentate gyrus in epileptic rats. *PLoS ONE* 8:e76051. <https://doi.org/10.1371/journal.pone.0076051>

- Bot AM, Dębski KJ, Lukasiuk K (2013b) Alterations in miRNA levels in the dentate gyrus in epileptic rats. *PLoS ONE* 8(10):e76051. <https://doi.org/10.1371/journal.pone.0076051>
- Dakterzada F, Targa A, Benítez ID, Romero-EIKhayat L, de Gonzalo-Calvo D, Torres G, Piñol-Ripoll G (2020) Identification and validation of endogenous control miRNAs in plasma samples for normalization of qPCR data for Alzheimer's disease. *Alzheimers Res Ther* 12:1–8. <https://doi.org/10.1186/s13195-020-00735-x>
- Dogini DB, Avansini SH, Vieira AS, Lopes-Cendes I (2013) MicroRNA regulation and dysregulation in epilepsy. *Front Cell Neurosci* 7:172. <https://doi.org/10.3389/fncel.2013.00172>
- Doxaki C, Kampranis SC, Eliopoulos AG, Spilianakis C, Tsatsanis C (2015) Coordinated regulation of miR-155 and miR-146a genes during induction of endotoxin tolerance in macrophages. *J Immunol* 195(12):5750–5761. <https://doi.org/10.4049/jimmunol.1500615>
- Engel J Jr (2001) A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology. *Epilepsia* 42:796–803. <https://doi.org/10.1046/j.1528-1157.2001.10401.x>
- Esquela-Kerscher A, Slack FJ (2006) Oncomirs—microRNAs with a role in cancer. *Nat Rev Cancer* 6:259–269. <https://doi.org/10.1038/nrc1840>
- Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE et al (2014) ILAE official report: a practical clinical definition of epilepsy. *Epilepsia* 55:475–482. <https://doi.org/10.1111/epi.12550>. Epub 2014 Apr 14. Review
- Gorter JA, Iyer A, White I, Colzi A, van Vliet EA, Sisodiya S, Aronica E (2014) Hippocampal subregion-specific microRNA expression during epileptogenesis in experimental temporal lobe epilepsy. *Neurobiol Dis* 62:508–520. <https://doi.org/10.1016/j.nbd.2013.10.026>
- Gross C, Yao X, Engel T, Tiwari D, Xing L, Rowley S, Bassell GJ (2016) MicroRNA-mediated downregulation of the potassium channel Kv4.2 contributes to seizure onset. *Cell Rep* 17(1):37–45. <https://doi.org/10.1016/j.celrep.2016.08.074>
- Guery D, Rheims S (2021) Clinical management of drug resistant epilepsy: a review on current strategies. *Neuropsychiatr Dis Treat* 17:2229–2242. <https://doi.org/10.2147/NDT.S256699>. Published online 12
- Hamdan FF, Myers CT, Cossette P, Lemay P, Spiegelman D, Laporte AD et al (2017) High rate of recurrent de novo mutations in developmental and epileptic encephalopathies. *Am J Hum Genet* 101:664–685. <https://doi.org/10.1016/j.ajhg.2017.09.008>
- He N, Lin ZJ, Wang J et al (2019) Evaluating the pathogenic potential of genes with de novo variants in epileptic encephalopathies. *Genet Med* 21:17–27. <https://doi.org/10.1038/s41436-018-0011-y>
- Holliday CJ, Ankeny RF, Jo H, Nerem RM (2011) Discovery of shear- and side-specific mRNAs and miRNAs in human aortic valvular endothelial cells. *American Journal of Physiology-Heart and Circulatory Physiology* 301(3):H856–H867. <https://doi.org/10.1152/ajpheart.00117.2011>
- Jimenez-Mateos EM, Engel T, Merino-Serrais P, McKiernan RC, Tanaka K, Mouri G et al (2012) Silencing microRNA-134 produces neuroprotective and prolonged seizure suppressive effects. *Nat Med* 18:1087–1094. <https://doi.org/10.1038/nm.2834>
- Kan AA, van Erp S, Derijck AA, de Wit M, Hessel EV, O'Duibhir E et al (2012) Genome-wide microRNA profiling of human temporal lobe epilepsy identifies modulators of the immune response. *Cell Mol Life Sci* 69:3127–3145. <https://doi.org/10.1007/s00018-012-0992-7>
- Kalser J, Cross JH (2018) The epileptic encephalopathy jungle - from Dr. West to the concepts of aetiology-related and developmental encephalopathies. *Curr Opin Neurol* 31:216–222. <https://doi.org/10.1097/WCO.0000000000000535>
- Karnati HK, Panigrahi MK, Gutti RK, Greig NH, Tamargo IA (2015) miRNAs: key players in neurodegenerative disorders and epilepsy. *J Alzheimers Dis* 48:563–580. <https://doi.org/10.3233/JAD-150395>
- Khan S, Al Baradie R (2012) Epileptic encephalopathies: an overview. *Epilepsy Research and Treatment* 2012:403592. <https://doi.org/10.1155/2012/403592>. Epub 2012 Nov 20
- Kretschmann A, Danis B, Andonovic L, Abnaof K, van Rikxoort M, Siegel F, Pfeifer A (2015) Different microRNA profiles in chronic epilepsy versus acute seizure mouse models. *J Mol Neurosci* 55(2):466–479. <https://doi.org/10.1007/s12031-014-0368-6>
- Li N, Pan J, Liu W, Li Y, Li F, Liu M (2020) MicroRNA-15a-5p serves as a potential biomarker and regulates the viability and apoptosis of hippocampus neuron in children with temporal lobe epilepsy. *Diagn Pathol* 15:1–7. <https://doi.org/10.1186/s13000-020-00944-w>
- Lu LF, Boldin MP, Chaudhry A, Lin LL, Taganov KD, Hanada T, Rudensky AY (2010) Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. *Cell* 142(6):914–929. <https://doi.org/10.1016/j.cell.2010.08.012>
- McKiernan RC, Jimenez-Mateos EM, Bray I, Engel T, Brennan GP, Sano T et al (2012) Reduced mature microRNA levels in association with dicer loss in human temporal lobe epilepsy with hippocampal sclerosis. *PLoS ONE* 7:e35921. <https://doi.org/10.1371/journal.pone.0035921>
- McTague A, Howell KB, Cross JH et al (2016) The genetic landscape of the epileptic encephalopathies of infancy and childhood. *Lancet Neurol* 15:304–316. [https://doi.org/10.1016/S1474-4422\(15\)00250-1](https://doi.org/10.1016/S1474-4422(15)00250-1)
- Mei J, Bachoo R, Zhang CL (2011) MicroRNA-146a inhibits glioma development by targeting Notch1. *Mol Cell Biol* 31(17):3584–3592. <https://doi.org/10.1128/MCB.05821-11>
- Mooney C, Becker BA, Raoof R, Henshall DC (2016) EpimiRBase: a comprehensive database of microRNA-epilepsy associations. *Bioinformatics* 32:1436–1438. <https://doi.org/10.1093/bioinformatics/btw008>
- Nguyen LS, Fregeac J, Bole-Feysot C, Cagnard N, Iyer A, Anink J, Colleaux L (2018) Role of miR-146a in neural stem cell differentiation and neural lineage determination: relevance for neurodevelopmental disorders. *Mol Autism* 9(1):1–12. <https://doi.org/10.1186/s13229-018-0219-3>
- Omran A, Peng J, Zhang C, Xiang QL, Xue J, Gan N, Yin F (2012) Interleukin-1 β and microRNA-146a in an immature rat model and children with mesial temporal lobe epilepsy. *Epilepsia* 53(7):1215–1224. <https://doi.org/10.1111/j.1528-1167.2012.03540.x>
- Patel J, Mercimek-Mahmutoglu S (2016) Epileptic encephalopathy in childhood: a stepwise approach for identification of underlying genetic causes. *Indian J Pediatr* 83:1164–1174. <https://doi.org/10.1007/s12098-015-1979-9>
- Pitkanen A, Lukasiuk K (2011) Mechanisms of epileptogenesis and potential treatment targets. *Lancet Neurol* 10:173–186. [https://doi.org/10.1016/S1474-4422\(10\)70310-0](https://doi.org/10.1016/S1474-4422(10)70310-0)
- Qin W, Liu Q, Xu X, Liu A, Zhang H, Gu J, Zhang T (2021) A novel Twist1/hsa-miR138-5p/caspase-3 pathway regulates cell proliferation and apoptosis of human multiple myeloma. *Ann Hematol* 100(7):1815–1824. <https://doi.org/10.1007/s00277-020-04059-6>
- Raga S, Specchio N, Rheims S, Wilmschurst JM (2021) Developmental and epileptic encephalopathies: recognition and approaches to care. *Epileptic Disord* 23:40–52. <https://doi.org/10.1684/epd.2021.1244>
- Reschke CR, Henshall DC (2015) microRNA and epilepsy. *Adv Exp Med Biol* 888:41–70. https://doi.org/10.1007/978-3-319-22671-2_4
- Scheffer IE, Liao J (2020) Deciphering the concepts behind “epileptic encephalopathy” and “developmental and epileptic encephalopathy.” *Eur J Paediatr Neurol* 24:11–14. [CrossRef]
- Sisodiya SM (2020) Epilepsy genetics and the precision medicine matrix. *Lancet Neurol* 19:29–30. [https://doi.org/10.1016/S1474-4422\(19\)30331-X](https://doi.org/10.1016/S1474-4422(19)30331-X)

- Suojalehto H, Lindström I, Majuri ML, Mitts C, Karjalainen J, Wolff H, Alenius H (2014) Altered microRNA expression of nasal mucosa in long-term asthma and allergic rhinitis. *Int Arch Allergy Immunol* 163(3):168–178. <https://doi.org/10.1159/000358486>
- Taganov KD, Boldin MP, Chang KJ, Baltimore D (2006) NF- κ B-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. *Proc Natl Acad Sci* 103(33):12481–12486. <https://doi.org/10.1073/pnas.0605298103>
- Tecuapetla CZ, Herrera MC, Munguia HL (2020) Insights into potential targets for therapeutic intervention in epilepsy. *Int J Mol Sci* 21:8573. <https://doi.org/10.3390/ijms21228573>. Published online 2020 Nov 13
- Tiwari D, Peariso K, Gross C (2018) MicroRNA-induced silencing in epilepsy: opportunities and challenges for clinical application. *Dev Dyn* 247(1):94–110. <https://doi.org/10.1002/dvdy.24582>
- Wang D, Xin L, Lin JH et al (2017) Identifying miRNA-mRNA regulation network of chronic pancreatitis based on the significant functional expression. *Medicine* 96:e6668. <https://doi.org/10.1097/md.0000000000006668>. PMID:28538367;PMCID:PMC5457847
- Wu X, Wang Y, Sun Z, Ren S, Yang W, Deng Y, Gao B (2019) Molecular expression and functional analysis of genes in children with temporal lobe epilepsy. *J Integr Neurosci* 18:71–77. <https://doi.org/10.31083/j.jin.2019.01.13>
- Zhang S, Kou Y, Hu C, Han Y (2017) MicroRNA profiling in the dentate gyrus in epileptic rats: the role of miR-187-3p. *Medicine* 96. <https://doi.org/10.1097/MD.0000000000006744>
- Zhao C, Zhou B, Cao J, Zhang Y, Li W, Wang M, Wang Y (2020) miR-187-3p participates in contextual fear memory formation through modulating SATB2 expression in the hippocampus. *NeuroReport* 31:909–917. <https://doi.org/10.1097/WNR.0000000000001484>

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.